Therapeutic Specialties Archives | 第 8 页，共 27 页 | Certara

Poster

Development of Paclitaxel PBPK Model to Predict Tumour Concentration in Cancer Patients

Danielle Pillsbury2019 年 6 月 24 日

Poster

Mechanistic models of cancer Mechanistic models cancer-immune cycle and immunotherapies

Danielle Pillsbury2019 年 6 月 24 日

Poster

Integration of a Tumour Growth Inhibition Model within a Mouse Physiologically-Based Pharmacokinetic Model

Danielle Pillsbury2019 年 6 月 24 日

White Paper

利用 QSP 优化免疫肿瘤药物发现与开发

A Quantitative Systems Pharmacology (QSP) approach for developing combination immune-oncology therapies can be used to…

Danielle Pillsbury2019 年 6 月 19 日

On-Demand Webinar

使用 RWD 进行高级分析可减轻 AD 药物开发和报销相关的风险

This webinar explained how advanced analytics using real-world data can mitigate challenges in Alzheimer’s disease…

Danielle Pillsbury2019 年 5 月 13 日

Poster

Population Pharmacokinetic Analysis of DS-8201a, A HER2-Targeting Antibody-Drug Conjugate, in Patients with HER2-Positive Breast Cancer or Other Solid Tumors

Danielle Pillsbury2019 年 5 月 2 日

Poster

Simulating the Impact of the Interplay Between CYP2C19 Polymorphisms and Ethnicity on Response to Clopidogrel, Using PBPK-PD Models

Danielle Pillsbury2019 年 4 月 22 日

Poster

Development of a Physiologically-Based Pharmacokinetic Model for Topical Lidocaine in Order to Predict Systemic Absorption in Healthy Volunteers, Geriatrics, and Pediatrics

Danielle Pillsbury2019 年 4 月 22 日

Poster

Exposure-Response Analyses to Support Dose Justification of DS-8201A, A HER2-Targeting Antibody-Drug Conjugate, in HER2-Positive Breast Cancer Patients

Danielle Pillsbury2019 年 4 月 22 日

Poster

Relationship of Ivosidenib Plasma Concentration to Heart Rate-Corrected QT Interval in Patients with IDH1-Mutant Advanced Hematologic Malignancies

Danielle Pillsbury2019 年 4 月 22 日

© 2025 Certara. 保留所有权力。 | 隐私政策

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software